Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners: A randomised, double blinded, placebo controlled study

M. Thalmann, G. H. Sodeck, S. Kavouras, A. Matalas, K. Skenderi, N. Yannikouris, H. Domanovits

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Ultra-endurance running is emerging as a popular sport in Western industrialised countries. Gastrointestinal bleeding has been reported to be an adverse effect in these runners. Objective: To see if the oral administration of a proton pump inhibitor would reduce the incidence of gastrointestinal bleeding in an ultramarathon. Methods: In a randomised, double blinded, placebo controlled study, a prophylactic regimen of three days of an oral proton pump inhibitor (pantoprazole 20 mg) was tested in healthy athletes participating in the Spartathlon ultramarathon. The incidence of gastrointestinal bleeding was assessed by a stool guaiac test. Results: Results were obtained for 70 healthy volunteers. The data for 20 of 35 runners in the intervention group and 17 of 35 runners in the placebo group were entered into the final analysis. At the end of the ultramarathon, two subjects in the intervention group and 12 in the placebo group had positive stool guaiac tests (risk difference 0.86; 95% confidence interval 0.45 to 0.96; p = 0.001). Conclusion: A short prophylactic regimen of oral proton pump inhibition can successfully decrease the incidence of gastrointestinal bleeding in participants in an ultramarathon.

Original languageEnglish (US)
Pages (from-to)359-362
Number of pages4
JournalBritish journal of sports medicine
Volume40
Issue number4
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Fingerprint

Proton Pumps
Guaiac
Placebos
Hemorrhage
Proton Pump Inhibitors
Incidence
Developed Countries
Running
Athletes
Sports
Oral Administration
Healthy Volunteers
Confidence Intervals

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners : A randomised, double blinded, placebo controlled study. / Thalmann, M.; Sodeck, G. H.; Kavouras, S.; Matalas, A.; Skenderi, K.; Yannikouris, N.; Domanovits, H.

In: British journal of sports medicine, Vol. 40, No. 4, 01.04.2006, p. 359-362.

Research output: Contribution to journalArticle

Thalmann, M. ; Sodeck, G. H. ; Kavouras, S. ; Matalas, A. ; Skenderi, K. ; Yannikouris, N. ; Domanovits, H. / Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners : A randomised, double blinded, placebo controlled study. In: British journal of sports medicine. 2006 ; Vol. 40, No. 4. pp. 359-362.
@article{9ff3533199c142c784da31432c5e74ab,
title = "Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners: A randomised, double blinded, placebo controlled study",
abstract = "Background: Ultra-endurance running is emerging as a popular sport in Western industrialised countries. Gastrointestinal bleeding has been reported to be an adverse effect in these runners. Objective: To see if the oral administration of a proton pump inhibitor would reduce the incidence of gastrointestinal bleeding in an ultramarathon. Methods: In a randomised, double blinded, placebo controlled study, a prophylactic regimen of three days of an oral proton pump inhibitor (pantoprazole 20 mg) was tested in healthy athletes participating in the Spartathlon ultramarathon. The incidence of gastrointestinal bleeding was assessed by a stool guaiac test. Results: Results were obtained for 70 healthy volunteers. The data for 20 of 35 runners in the intervention group and 17 of 35 runners in the placebo group were entered into the final analysis. At the end of the ultramarathon, two subjects in the intervention group and 12 in the placebo group had positive stool guaiac tests (risk difference 0.86; 95{\%} confidence interval 0.45 to 0.96; p = 0.001). Conclusion: A short prophylactic regimen of oral proton pump inhibition can successfully decrease the incidence of gastrointestinal bleeding in participants in an ultramarathon.",
author = "M. Thalmann and Sodeck, {G. H.} and S. Kavouras and A. Matalas and K. Skenderi and N. Yannikouris and H. Domanovits",
year = "2006",
month = "4",
day = "1",
doi = "10.1136/bjsm.2005.024463",
language = "English (US)",
volume = "40",
pages = "359--362",
journal = "British Journal of Sports Medicine",
issn = "0306-3674",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners

T2 - A randomised, double blinded, placebo controlled study

AU - Thalmann, M.

AU - Sodeck, G. H.

AU - Kavouras, S.

AU - Matalas, A.

AU - Skenderi, K.

AU - Yannikouris, N.

AU - Domanovits, H.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: Ultra-endurance running is emerging as a popular sport in Western industrialised countries. Gastrointestinal bleeding has been reported to be an adverse effect in these runners. Objective: To see if the oral administration of a proton pump inhibitor would reduce the incidence of gastrointestinal bleeding in an ultramarathon. Methods: In a randomised, double blinded, placebo controlled study, a prophylactic regimen of three days of an oral proton pump inhibitor (pantoprazole 20 mg) was tested in healthy athletes participating in the Spartathlon ultramarathon. The incidence of gastrointestinal bleeding was assessed by a stool guaiac test. Results: Results were obtained for 70 healthy volunteers. The data for 20 of 35 runners in the intervention group and 17 of 35 runners in the placebo group were entered into the final analysis. At the end of the ultramarathon, two subjects in the intervention group and 12 in the placebo group had positive stool guaiac tests (risk difference 0.86; 95% confidence interval 0.45 to 0.96; p = 0.001). Conclusion: A short prophylactic regimen of oral proton pump inhibition can successfully decrease the incidence of gastrointestinal bleeding in participants in an ultramarathon.

AB - Background: Ultra-endurance running is emerging as a popular sport in Western industrialised countries. Gastrointestinal bleeding has been reported to be an adverse effect in these runners. Objective: To see if the oral administration of a proton pump inhibitor would reduce the incidence of gastrointestinal bleeding in an ultramarathon. Methods: In a randomised, double blinded, placebo controlled study, a prophylactic regimen of three days of an oral proton pump inhibitor (pantoprazole 20 mg) was tested in healthy athletes participating in the Spartathlon ultramarathon. The incidence of gastrointestinal bleeding was assessed by a stool guaiac test. Results: Results were obtained for 70 healthy volunteers. The data for 20 of 35 runners in the intervention group and 17 of 35 runners in the placebo group were entered into the final analysis. At the end of the ultramarathon, two subjects in the intervention group and 12 in the placebo group had positive stool guaiac tests (risk difference 0.86; 95% confidence interval 0.45 to 0.96; p = 0.001). Conclusion: A short prophylactic regimen of oral proton pump inhibition can successfully decrease the incidence of gastrointestinal bleeding in participants in an ultramarathon.

UR - http://www.scopus.com/inward/record.url?scp=33645677019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645677019&partnerID=8YFLogxK

U2 - 10.1136/bjsm.2005.024463

DO - 10.1136/bjsm.2005.024463

M3 - Article

C2 - 16556794

AN - SCOPUS:33645677019

VL - 40

SP - 359

EP - 362

JO - British Journal of Sports Medicine

JF - British Journal of Sports Medicine

SN - 0306-3674

IS - 4

ER -